Literature DB >> 3120473

Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.

M J Pippard1.   

Abstract

This paper reviews the factors governing the rate of iron loading and iron toxicity in the thalassaemia syndromes and sickle cell disease. It outlines the main determinants of iron mobilization by the iron-chelating drug, desferrioxamine, together with the effects of this drug in clinical practice.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3120473     DOI： 10.1159/000205876

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


  8 in total

1.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 2.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; James S McManis; Shailendra Singh
Journal:  Biometals       Date:  2010-11-20       Impact factor: 2.949

4.  Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis.

Authors:  T Güngör; E Rohrbach; E Solem; J P Kaltwasser; B Kornhuber
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791

5.  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; James S McManis
Journal:  J Med Chem       Date:  2012-08-13       Impact factor: 7.446

Review 6.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

7.  Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major.

Authors:  Casey J Brewer; Thomas D Coates; John C Wood
Journal:  J Magn Reson Imaging       Date:  2009-02       Impact factor: 4.813

Review 8.  A Review on Iron Chelators in Treatment of Iron Overload Syndromes.

Authors:  Naser Mobarra; Mehrnoosh Shanaki; Hassan Ehteram; Hajar Nasiri; Mehdi Sahmani; Mohsen Saeidi; Mehdi Goudarzi; Hoda Pourkarim; Mehdi Azad
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-10-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.